Pyrazinamide

Pyrazinecarboxamide

J04AK01

White solid

Tubercular agents

189-191 ° C

• Soluble in water and ethanol
• Poorly in diethyl ether

Template: Infobox chemical / molecular formula search available

Pyrazinamide is a tuberculostatic which, bactericidal effect on Mycobacterium tuberculosis, the causative agent of tuberculosis, but not the bovine form ( Mycobacterium bovis ) or atypical mycobacteria. If the active ingredient used in the initial phase, it shortens the therapy and reduces the frequency of recurrences.

The mechanism of action is not yet known. What is certain is that the active ingredient in the form of pyrazine carboxylic acid accumulates in the pathogens, is cleaved by an amidase and the bacteria can no longer rely on this way. It is believed that it - like isoniazid - with NAD interferes.

Pyrazinamide is administered orally. It passes the blood- brain-barrier, has a half -life of ten to twelve hours, and is excreted by the kidneys. At low pH values ​​, it works better than at high, particularly effective it is against intracellularly located bacteria and germs in verkäsendem tuberculous, dead tissue.

Side effects

Note the liver toxicity, permanent monitoring of the liver parameters is necessary. In addition, allergic reactions such as increased sensitivity to light, platelet deficiency or sideroblastic anemia may occur. Pyrazinamide reduces the excretion of uric acid, causing the uric acid concentration in plasma rises ( hyperuricaemia ). This can lead to the triggering of an acute attack of gout.

Trade names

Pyrafat (D, A ), various generics (D, A, CH)

Rifater (D, A, CH), Rimstar (CH), Tebesium Trio ( D)